Upstate Active Clinical Trials

Study Title:

GOG-3086: REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice (IC) Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)

What is the purpose of the study? (in Layman's terms, please describe the study)

A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1

Upstate Institutional Review Board (IRB) Number:

2191487

Study/Protocol ID:

GOG-3086

Study Phase:

3

Patient Age Group:

Adults

Principal Investigator:

Mary J Cunningham, MD

Who is eligible?

High-grade serous epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer with pathology report documentation of tumor type.
Age 18 <
Total of 3 previous regimens
1 measurable lesion

What is involved if I participate?

• How long is the study?
  5 years
• Is transportation provided or reimbursed?
  No
• Is parking provided or reimbursed?
  No
• What tests and procedures are involved?
  Labs, ECHO, EKG, CT/MRI, tissue submittal, eye exam, etc

Where will the study take place?

Cancer Center or Madison Irving - Gynecology

Other Information:

N/A

Who can I contact for more information?

Name: Sarah Clark, BS
Phone: 315-464-8276
Email: [email protected]

Return to Previous Page || Search Again